Semaglutide
Lyophilized research reference material. Released with a per-lot Certificate of Analysis. For laboratory research use only.
- All products currently listed on this site are for research purposes ONLY.
- All products sold on this website are intended for research and identification purposes only.
- These products are not intended for human dosing, injections, or ingestion.
- Peptides are strictly for laboratory, academic, or institutional research and not for human or animal consumption.
Research background
Semaglutide is a long-acting GLP-1 receptor agonist structurally based on human GLP-1 (94% homology), modified with amino-acid substitutions and a C18 fatty-acid chain that confers albumin binding and resistance to DPP-4 degradation. It is studied as a stabilized analog of the native incretin.
The compound has an extensive randomized controlled evidence base (the SUSTAIN, PIONEER, and STEP programs) characterizing its metabolic activity.
Summary of published scientific literature provided for laboratory research reference only. It is not a claim of safety, efficacy, or suitability for any use, and does not describe or recommend any human or veterinary use.
Selected references
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016;375(19):1834-1844.
- Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology. 2019;10:155.
Trademarks & attribution
Semaglutide is the active ingredient marketed as Ozempic(R), Wegovy(R), and Rybelsus(R) by Novo Nordisk. Those trademarks are the property of Novo Nordisk. Catalyst Research Labs is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Supplied as reference material only.
